Omeros (NASDAQ:OMER) Stock Passes Above 200-Day Moving Average of $3.00

Omeros Co. (NASDAQ:OMER) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.00 and traded as high as $3.82. Omeros shares last traded at $3.38, with a volume of 429,470 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd.

Omeros Price Performance

The company’s 50 day moving average price is $3.90 and its 200 day moving average price is $3.00. The firm has a market capitalization of $193.53 million, a P/E ratio of -1.84 and a beta of 1.34.

Hedge Funds Weigh In On Omeros

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. bought a new position in shares of Omeros during the second quarter worth $27,000. Farther Finance Advisors LLC bought a new position in shares of Omeros during the second quarter worth $33,000. Tower Research Capital LLC TRC boosted its position in shares of Omeros by 199.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,069 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 5,378 shares in the last quarter. ExodusPoint Capital Management LP bought a new position in shares of Omeros during the first quarter worth $54,000. Finally, Alliancebernstein L.P. bought a new position in shares of Omeros during the second quarter worth $64,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.